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GENERAL COMMENTS
this is a timely and well designed trial. distinguishing radiation toxicity from radiation + radiation sensitizer (AGuIX®) toxicity is always a challenge. elaborating on how the authors plan on achieving this, would be a welcome addition to the protocol. this is my only criticism of this trial.
REVIEWER
James F. Hainfeld Nanoprobes, Inc. USA REVIEW RETURNED 14-Jun-2018 GENERAL COMMENTS This is a technically proficient protocol for a phase 1 clinical trial. It appears that hospital approvals and regulatory safeguards are properly in place, and that the trial is well-designed. The continuing dire situation that patients with brain metastases face emphasizes the urgent need for new, better treatments. The use of the novel gadolinium nanoparticle AGuIX® could provide a new treatment. The purpose of this Phase 1 trial is to assess the safety and tolerance of AGuIX® in combination with whole brain radiotherapy (WBRT) in patients with multiple brain metastases.
The authors should be praised for doing extensive preclinical work and also developing the scaled up production and quality control of this new nanomaterial. Preclinical testing was performed in cells (in vitro), mice, rats, and even monkeys. Its use as a new longer blood half-life MRI contrast agent appears interesting as well as serving to quantify tumor delivery and assist in dose planning.
However, unfortunately, upon review of the previous publications by the authors, it appears that there is not sufficient preclinical data to support transition to humans at this point. These deficiencies should be corrected before proceeding to a clinical trial.
There are two noted questions that need to be addressed: 1. Most of the reported radiation enhancement was performed with kilovolt energy X-rays: Kotb et al., 2013 , Sancey et al., 2014 , Dufort et al., 2015 , LeDuc et al., 2011 , and Miladi et al., 2015 . Luchett et al., 2014 did an in vitro cell study comparing kV and MV but this showed the survival error bars overlapping for the MV case without clear significance for benefit, whereas the kV error bars did show error bar separation and clear benefit. It is well known that kV radiation is physically even >100 times more beneficial for high atomic number radioenchancement compared to MV. Some Monte Carlo calculations indicate Au having a 200% dose increase compared to a 6MV enhancement of 0.7% (i.e., negligible). A few gold nanoparticle studies have shown benefit using 6MV, but need to invoke poorly understood 'biological effects'. The only in vivo radiation enhancement study reported to support this trial with 6MV was that by Verry et al., 2016 . This used the 9LGS rat orthotopic glioma model. The median survival (the metric usually reported) was a survival of 38 days for radiotherapy (RT) only and 37 days for RT+ AGuIX® (i.e., no significant difference). The only 'hope' for a better result was that one rat in the RT+Gd group lived a very long time and appeared cured. However, this is a very immunogenic tumor and other investigators find that in an experiment with many 9LGS rats it is not uncommon to see one have a spontaneous CR. So although the preclinical studies seem to validate the AGuIX® is not toxic, there is really no credible evidence that at the doses used there is any significant benefit when combined with 6MV RT. Without this evidence, proceeding to a Phase 1 clinical trial may serve to establish the safety of IV administered AGuIX®, but ultimately present false hope to victims suffering from brain metastases and be wasteful of resources. Additional 6MV preclinical studies are recommended to better assess the possible benefit of AGuIX®-RT. 2. "The goal of this study is to perform the first in human injection, to evaluate the safety and to determine the maximum-tolerated dose of AGuIX® combined with WBRT". "Five dose escalation cohorts are planned: 15,30, 50, 75 and 100 mg/kg." Here the study stops at 100 mg/kg, where in preclinical studies in monkeys a 'high' tolerated dose was 450 mg/kg. Why are not higher doses included if it is desired to find the maximum tolerated dose?

Paolo Borghetti
Radiation oncology department, Spedali Civili an University of Brescia, Italy REVIEW RETURNED 23-Jun-2018
GENERAL COMMENTS
The reviewer completed the checklist but made no further comments.
VERSION 1 -AUTHOR RESPONSE Reviewer: 1
We thank the reviewer for this relevant remark. It is indeed challenging to distinguish radiation toxicity from radiation + radiosensitizer toxicity.
All toxicities are assessed case by case by an independent monitoring committee. Elements taken into account are mainly the nature of the adverse event and the time of occurrence with respect to the administration of the radiosensitizer. Moreover each adverse event is analyzed by the pharmacovigilance department.
Reviewer: 2
We thank the reviewer for these positive remarks and the highlighting of the extensive preclinical work done to establish the proof of concept of the radiosensitizing effect of AGuIX® nanoparticles.
The transition to humans is a very long and complicated process. The authors asked themselves many questions, including sufficient preclinical data, before conducting this clinical trial. In addition, we would like to remind that this clinical protocol has been evaluated and authorized by the French regulatory authorities (French national agency of medicines and health products safety), and that the first patients have already been included.
The preclinical proof of efficacy was established on six different tumor models treated by different irradiation protocols, including 6 MV photons irradiation (+ 60 publications).
1-Concerning the data obtained with 6 MV irradiation on 9LGS orthotopic glioma model, we agree that the median survival was not improve. However, the radiosensitizing effect of the combination of the nanoparticles with 6 MV irradiation was demonstrated by the significant decrease of tumor size observed on MRI one week after treatment start. Furthermore, another study was performed, at the Dana Farber Cancer Institute -Harvard Medical School, on subcutaneous pancreatic tumor (Capan-1) in order to compare 220 kV preclinical irradiation and 6 MV clinical irradiation (Detappe et al., J Control Release, 2016) . In this study, they demonstrated that a single fraction of 10 Gy (6 MV irradiation) performed 15 minutes after injection induced a significant reduction of 50 % of tumor growth, and a significant ILS of 56%, compared to radiation alone. These results are comparable with those obtained with 220kV irradiation, i.e. a significant reduction of 65 % of tumor growth, and a significant ILS of 71%, compared to radiation alone.
All preclinical data obtained on AGuIX® nanoparticles, in terms of tumor targeting, MRI visualization and efficacy (kV and MV irradiations), justify the transfer to patients and the conduction of the phase I clinical trial NANO-RAD.
2-The target dose of 100 mg/kg was defined from doses used in the different efficacy studies and from regulatory toxicology studies performed on rats and monkeys. Higher doses have actually been evaluated in monkeys without occurrence of adverse events, with a "high" tolerated dose of 450 mg/kg corresponding to a Human Equivalent Dose of 150 mg/kg. We did not wish to further increase the dose. We plan to repeat the injections, for example with an injection at the beginning of each week of radiotherapy, in order to maintain the radiosensitizing effect throughout the irradiation treatment.
VERSION 2 -REVIEW
REVIEWER
James F. Hainfeld Nanoprobes, Inc. U.S.A.
REVIEW RETURNED
17-Aug-2018
GENERAL COMMENTS
Best wishes for the success of your trial and patient benefit.
